Patient Preference Study in Type-2 Diabetes Mellitus: Discrete Choice Experiment (DCE) to Support Novo Nordisk's Long-Acting Insulin

Novo Nordisk

Status

Completed

Conditions

Type-2 Diabetes Mellitus (T2DM)

Treatments

Other: No treatment given

Study type

Observational

Funder types

Industry

Identifiers

NCT06592950

DAS-7791

U1111-1293-3919 (Other Identifier)

Details and patient eligibility

About

The primary objective of this research is to assess T2DM patient preferences for a once weekly insulin treatment. The study involves a qualitative interview phase and quantitative survey phase with a Discrete Choice Experiment (DCE).

Enrollment

513 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient is an adult aged 18 years or over
Patient was diagnosed with type-2 diabetes mellitus (T2DM) greater than or equal to 180 days prior to the day of screening
Patient is currently prescribed a diabetes treatment (e.g., Metformin/Sus, DPP4i, SGLT2i, GLP-1 RA and/or basal insulin)
Patient is willing and able to provide written informed consent to participate

For qualitative interviews:

Patient is a fluent speaker of English and is able to read, write, and fully understand the English language
Patient is a resident in Canada

For quantitative online survey:

Patient is a fluent speaker of the local language (English/French/Spanish or Japanese) and is able to read, write and fully understand the local language
Patient is a resident of either Canada, France, Spain or Japan

Exclusion criteria

Patient is currently employing a basal-bolus insulin treatment regimen to manage their diabetes
Patient is unwilling or unable to comply with the needs of the study or has a physical, behavioural or mental condition that, in the opinion of the recruiter may affect the patient's ability to take part in the study, understand the nature, scope and possible consequences of the study, or the responses they might provide.